BTIG Maintains Buy on Xtant Medical Hldgs, Raises Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Xtant Medical Holdings (AMEX:XTNT) and raises the price target from $2 to $3.
May 16, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman has maintained a Buy rating on Xtant Medical Holdings and raised the price target from $2 to $3.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100